olfactory receptor family 5 subfamily BT member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR5BT1P profile across patient tissues and cancer cell-line models. OR5BT1P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, OR5BT1P is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, OR5BT1P RNA expression shows 13,191 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KICH, and THYM as cancer lineages where OR5BT1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5BT1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5BT1P survival associations across molecular data types. OR5BT1P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5BT1P RNA expression–survival associations across cancer types. High OR5BT1P expression shows unfavorable associations in COAD, LIHC and KIRC, but favorable associations in BLCA, ESCA and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for OR5BT1P RNA expression.
This table summarizes OR5BT1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for OR5BT1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5BT1P shows lower tumor expression in KICH, LUAD and LUSC. The KICH box plot shows higher OR5BT1P RNA expression in normal versus tumor tissue (log2 FC = −0.056, t-test p = .007).
This table shows molecular features associated with OR5BT1P in patient tissues and cancer cell lines. In patient samples, OR5BT1P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
